Angiogenesis and antiangiogenic approaches to sarcomas

Current Opinion in Oncology

Volumn 13, Issue 4, 2001, Pages 261-269

  Heymach, John V ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 4 DEDIMETHYLAMINOSANCYCLINE; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; CILENGITIDE; FUMAGILLOL CHLOROACETYLCARBAMATE; IM 862; INTERLEUKIN 12; MONOCLONAL ANTIBODY LM 609; PENTOSAN POLYSULFATE; TECOGALAN; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG RESPONSE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMA; SIDE EFFECT; SOFT TISSUE SARCOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0034961691     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200107000-00009     Document Type: Review

References (85)

1. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas: Implications for decision making in the clinic
2. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens: A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
3. Clinical applications of research on angiogenesis
4. Tumor angiogenesis: Therapeutic implications
5. Tumor dormancy in vivo by prevention of neovascularization
6. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
7. Angiogenesis in cancer and other diseases
8. Angiogenesis: Regulators and clinical applications
9. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
10. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
11. Vascular-specific growth factors and blood vessel formation
12. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
13. VEGF is required for growth and survival in neonatal mice
14. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
15. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
16. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
17. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta
18. Genes expressed in human tumor endothelium
19. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
20. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma
21. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
22. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer
23. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma
24. Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours
25. Different patterns of angiogenesis in sarcomas and carcinomas
26. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas
27. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors
28. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas
29. Plasma MMP-9 activity in soft tissue sarcomas
30. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma
31. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis
32. Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma
33. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
34. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
35. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression
36. p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma
37. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas
38. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
39. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
40. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways
41. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
42. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma
43. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer
44. Prognostic significance of microvessel density in lymph node negative breast carcinoma
45. Angiogenesis in malignant fibrous histiocytoma
46. Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcomas
47. Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas
48. Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma
49. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
50. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
51. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
52. Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470
53. The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice
54. Phase II trials of interferons-alpha and -beta in advanced sarcomas
55. Thalidomide is an inhibitor of angiogenesis
56. Current role of thalidomide in cancer treatment
57. Antitumor activity of thalidomide in refractory multiple myeloma
58. A pilot study of an angiogenesis inhibitor vitaxin in patients with advanced leiomyosarcomas (Leios)
59. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma
60. Update on hemangiomas and vascular malformations
61. The role of vascular endothelial growth factor (VEGF) in AIDS-retated Kaposi's sarcoma
62. Update on the pathogenesis and treatment of Kaposi sarcoma
63. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome
64. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy
65. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a
66. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study
67. Activity of thalidomide in AIDS-related Kaposi's sarcoma
68. A multicenter dose-escalating study of SU5416 in AIDS-related Kaposi's sarcoma
69. Angiogenesis inhibitor Col-3 in the treatment of HIV-related Kaposi's sarcoma: A phase I AIDS Malignancy Consortium study
70. Molecular portraits of human breast tumours
71. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
72. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications
73. Phase I dose-escalating trial of oral SU006668, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies
74. Combined effects of angiostatin and ionizing radiation in antitumour therapy
75. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation
76. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel
77. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
78. Phase I study of the angiogenesis inhibitor TNP-470 (T) in combination with paclitaxel (P) in patients with solid tumors
79. Phase I study of the combination of TNP-470 and paclitaxel in patients with advanced CANCER
80. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
81. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma
82. Angiogenic properties of human immunodeficiency virus type 1 Tat protein
83. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma
84. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium